CARL CHRISTOPHER HOOK M.D.
Prescription History 1508836743
Internal Medicine - Hematology in Rochester, MN

NPI Status: Active since January 23, 2006

Contact Information

200 1ST ST SW
ROCHESTER, MN
ZIP 55905
Phone: (507) 284-2511

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CARL CHRISTOPHER HOOK M.D., an active Hematology specialist practicing in Rochester, MN. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 208 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 35 claims alone.


Allopurinol

Generic Formulation: AllopurinolSpecialty: Hematology
Provider Metrics Summary
Total Claims 12
30-Day Fills 24.0
Days Supply 720
MN State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills105.2
Peer Average Days Supply3,098
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.1% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $51.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.31

State Avg Cost Per Claim

$16.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Cephalexin

Generic Formulation: CephalexinSpecialty: Hematology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 375
MN State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply337
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $276.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.74

State Avg Cost Per Claim

$7.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology
Provider Metrics Summary
Total Claims 16
30-Day Fills 24.0
Days Supply 720
MN State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills91.9
Peer Average Days Supply2,594
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.8% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,530.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$845.66

State Avg Cost Per Claim

$877.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Hydromorphone Hcl

Generic Formulation: Hydromorphone HclSpecialty: Hematology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 94
MN State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.0
Peer Average Days Supply189
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.3% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.17

State Avg Cost Per Claim

$90.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Hydromorphone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology
Provider Metrics Summary
Total Claims 35
30-Day Fills 96.2
Days Supply 2,885
MN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills67.1
Peer Average Days Supply1,966
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,294.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.97

State Avg Cost Per Claim

$33.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology
Provider Metrics Summary
Total Claims 24
30-Day Fills 32.0
Days Supply 944
MN State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.5
Peer Average Days Supply633
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,363.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$765.14

State Avg Cost Per Claim

$1,985.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Hematology
Provider Metrics Summary
Total Claims 15
30-Day Fills 41.0
Days Supply 1,230
MN State Average Benchmarks
Peer Average Claims126.0
Peer Average 30-Day Fills286.0
Peer Average Days Supply8,339
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 88.1% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $348.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.21

State Avg Cost Per Claim

$19.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Oxycontin

Generic Formulation: Oxycodone HclSpecialty: Hematology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
MN State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.5
Peer Average Days Supply647
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.2% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,005.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,455.09

State Avg Cost Per Claim

$612.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve severe ongoing pain (such as due to cancer). Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain. The higher strengths of this drug (more than 40 milligrams per tablet) should be used only if you have been regularly taking moderate to large amounts of an opioid pain medication. These strengths may cause overdose (even death) if taken by a person who has not been regularly taking opioids. Do not use the extended-release form of oxycodone to relieve pain that is mild or that will go away in a few days. This medication is not for occasional (as needed) use.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology
Provider Metrics Summary
Total Claims 32
30-Day Fills 63.0
Days Supply 1,827
MN State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills54.3
Peer Average Days Supply1,087
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $437.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.68

State Avg Cost Per Claim

$7.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Hematology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 620
MN State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.6
Peer Average Days Supply438
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $70,838.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,219.93

State Avg Cost Per Claim

$12,285.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology
Provider Metrics Summary
Total Claims 16
30-Day Fills 20.0
Days Supply 600
MN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills64.9
Peer Average Days Supply1,855
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.9% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,194.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$762.17

State Avg Cost Per Claim

$960.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CARL CHRISTOPHER HOOK M.D. provides transparency into local medical care patterns within Rochester, MN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.